Robert Hazlett
Stock Analyst at BTIG
(1.29)
# 3,544
Out of 5,182 analysts
22
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.96 | +244.83% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $86.74 | -30.82% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.89 | +1,473.21% | 2 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $187.40 | -47.71% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.54 | +983.03% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $8.89 | +608.66% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $10.79 | +168.77% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.03 | +2,524,171.84% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.42 | +322.54% | 2 | Sep 4, 2020 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $18 | $19.16 | -6.05% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.96
Upside: +244.83%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $86.74
Upside: -30.82%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.89
Upside: +1,473.21%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $187.40
Upside: -47.71%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.54
Upside: +983.03%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $8.89
Upside: +608.66%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $10.79
Upside: +168.77%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.03
Upside: +2,524,171.84%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.42
Upside: +322.54%
KalVista Pharmaceuticals
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $19.16
Upside: -6.05%